Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Epistemonikos ID: 0ed67c0fdcc63ecbd6ae2ad2a628f56c06971560
First added on: May 14, 2024